{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:45:59Z","timestamp":1773837959630,"version":"3.50.1"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2892,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Autoimmune hepatitis may fail to respond to corticosteroid therapy, but the frequency and bases for this outcome are uncertain. We aimed to determine the frequency and nature of treatment failure in patients with type 1 autoimmune hepatitis, define features associated with its occurrence, and assess if the model for end-stage liver disease can predict this outcome. Patients failing conventional corticosteroid regimens were compared to patients who responded to similar regimens. Fourteen of 214 patients (7%) failed corticosteroid treatment. Patients who failed therapy were younger (33 \u00b1 3 years versus 48 \u00b1 1 years,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.0008), had higher serum levels of bilirubin at accession (4.1 \u00b1 0.9 mg\/dL versus 2.3 \u00b1 0.2 mg\/dL,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.02), presented acutely more frequently (43% versus 14%,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.01), and had a higher frequency of HLA (human leukocyte antigen) DRB1*03 (93% versus 53%,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.004) than did patients who achieved remission. An alternative disease (fatty liver disease) emerged in only 1 patient who failed therapy (7%). Scores determined by the model of end-stage liver disease at presentation of patients who failed treatment were higher than those of who achieved remission (16 \u00b1 1 versus 10 \u00b1 0.3 points,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>&lt; 0.0001), and score greater than 12 points had greater sensitivity (97%) and specificity (68%) for treatment failure than did HLA DRB1*03 or other features.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Onset at an early age, acute presentation, hyperbilirubinemia, and presence of HLA DRB1*03 characterize patients who fail corticosteroid treatment. The model for end-stage liver disease may be a useful instrument for identifying patients prone to this outcome. (HEPATOLOGY 2007.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21787","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T01:19:13Z","timestamp":1186017553000},"page":"1138-1145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":118,"title":["Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease"],"prefix":"10.1097","volume":"46","author":[{"given":"Aldo J.","family":"Montano-Loza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herschel A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Czaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-24-20241201","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"R2-24-20241201","first-page":"221","article-title":"Failure of customary treatment in chronic active liver disease: causes and management.","volume":"8","author":"Schalm","year":"1976","journal-title":"Ann Clin Res"},{"key":"R3-24-20241201","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S1089-3261(02)00028-4","article-title":"Treatment strategies in autoimmune hepatitis.","volume":"6","author":"Czaja","year":"2002","journal-title":"Clin Liver Dis"},{"key":"R4-24-20241201","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/hep.510300603","article-title":"Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebocontrolled treatment trial.","volume":"30","author":"Czaja","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R5-24-20241201","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Shortterm cyclosporine induces a remission of autoimmune hepatitis in children.","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R6-24-20241201","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"CyclosporinA is a promising alternative to corticosteroids in autoimmune hepatitis.","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"R7-24-20241201","first-page":"771","article-title":"Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an openlabel preliminary trial.","volume":"90","author":"Van Thiel","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"R8-24-20241201","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis.","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R9-24-20241201","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","article-title":"Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine.","volume":"33","author":"Richardson","year":"2000","journal-title":"J Hepatol"},{"key":"R10-24-20241201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy.","volume":"18","author":"Devlin","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"R11-24-20241201","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in nontransplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int"},{"key":"R12-24-20241201","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.","volume":"39","author":"Czaja","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R13-24-20241201","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis report of three cases.","volume":"35","author":"Kanzler","year":"1997","journal-title":"Z Gastroenterol"},{"key":"R14-24-20241201","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0168-8278(98)80128-1","article-title":"Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate.","volume":"29","author":"Burak","year":"1998","journal-title":"J Hepatol"},{"key":"R15-24-20241201","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","article-title":"Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature.","volume":"26","author":"Santos","year":"2006","journal-title":"Liver Int"},{"key":"R16-24-20241201","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","article-title":"Failure of budesonide in a pilot study of treatmentdependent autoimmune hepatitis.","volume":"119","author":"Czaja","year":"2000","journal-title":"Gastroenterology"},{"key":"R17-24-20241201","first-page":"13","article-title":"Efficacy of intravenous immunoglobulin therapy in a case of autoimmunemediated chronic active hepatitis.","volume":"10","author":"Carmassi","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"R18-24-20241201","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/BF02934123","article-title":"Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy.","volume":"32","author":"Swada","year":"1997","journal-title":"J Gastroenterol"},{"key":"R19-24-20241201","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R20-24-20241201","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0168-8278(05)80394-0","article-title":"Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: a case report.","volume":"21","author":"Horsmans","year":"1994","journal-title":"J Hepatol"},{"key":"R21-24-20241201","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0168-8278(92)90178-R","article-title":"Frequency and significance of chronic ulcerative colitis in severe corticosteroidtreated autoimmune hepatitis.","volume":"14","author":"Perdigoto","year":"1992","journal-title":"J Hepat"},{"key":"R22-24-20241201","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1007\/BF01296509","article-title":"Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis.","volume":"37","author":"Rabinovitz","year":"1992","journal-title":"Dig Dis Sci"},{"key":"R23-24-20241201","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0168-8278(96)80266-2","article-title":"Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.","volume":"24","author":"Gohlke","year":"1996","journal-title":"J Hepatol"},{"key":"R24-24-20241201","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1572-0241.1998.224_a.x","article-title":"Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases.","volume":"93","author":"McNair","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R25-24-20241201","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02063938","article-title":"Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis.","volume":"40","author":"Czaja","year":"1995","journal-title":"Dig Dis Sci"},{"key":"R26-24-20241201","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0016-5085(84)90603-6","article-title":"Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatichepatocellular injury in humans.","volume":"86","author":"DePinho","year":"1984","journal-title":"Gastroenterology"},{"key":"R27-24-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep.1840090205","article-title":"The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients.","volume":"9","author":"Hay","year":"1989","journal-title":"HEPATOLOGY"},{"key":"R28-24-20241201","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hep.510250211","article-title":"Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.","volume":"25","author":"Czaja","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R29-24-20241201","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","article-title":"Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis.","volume":"117","author":"Czaja","year":"1999","journal-title":"Gastroenterology"},{"key":"R30-24-20241201","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.510310110","article-title":"CTLA4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis.","volume":"31","author":"Agarwal","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R31-24-20241201","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-0039.2006.00794.x","article-title":"A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis.","volume":"69","author":"Agarwal","year":"2007","journal-title":"Tissue Antigens"},{"key":"R32-24-20241201","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2004.02.010","article-title":"Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.","volume":"40","author":"Said","year":"2004","journal-title":"J Hepatol"},{"key":"R33-24-20241201","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"The model for endstage liver disease (MELD).","volume":"45","author":"Kamath","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R34-24-20241201","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.","volume":"31","author":"Malinchoc","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R35-24-20241201","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/gast.2003.50016","article-title":"United Network for Organ Sharing Liver Disease Severity Score Committee. Model for endstage liver disease (MELD) and allocation of donor livers.","volume":"124","author":"Wiesner","year":"2003","journal-title":"Gastroenterology"},{"key":"R36-24-20241201","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis.","volume":"41","author":"Dunn","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R37-24-20241201","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.","volume":"41","author":"Alessandria","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R38-24-20241201","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.transproceed.2006.06.004","article-title":"MELD score as a prognostic model for listing acute liver failure patients for liver transplantation.","volume":"38","author":"Zaman","year":"2006","journal-title":"Transplant Proc"},{"key":"R39-24-20241201","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1053\/j.gastro.2005.09.024","article-title":"Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score.","volume":"129","author":"Terra","year":"2005","journal-title":"Gastroenterology"},{"key":"R40-24-20241201","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/lt.20666","article-title":"The MELD score as a predictor of nontransplant surgical mortality in patients with cirrhosis.","volume":"12","author":"Perkins","year":"2006","journal-title":"Liver Transpl"},{"key":"R41-24-20241201","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1440-1746.2006.04510.x","article-title":"Prediction of the prognosis in patients with acuteonchronic hepatitis using the MELD scoring system.","volume":"21","author":"Yu","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R42-24-20241201","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/jhep.2002.34944","article-title":"Diagnosis and treatment of autoimmune hepatitis.","volume":"36","author":"Czaja","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R43-24-20241201","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"key":"R44-24-20241201","first-page":"1206","article-title":"The validity and importance of subtypes of autoimmune hepatitis: a point of view.","volume":"90","author":"Czaja","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"R45-24-20241201","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.510240515","article-title":"Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis.","volume":"24","author":"Czaja","year":"1996","journal-title":"HEPATOLOGY"},{"key":"R46-24-20241201","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1023\/A:1018809431189","article-title":"Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis.","volume":"42","author":"Czaja","year":"1997","journal-title":"Dig Dis Sci"},{"key":"R47-24-20241201","first-page":"993","article-title":"Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods.","volume":"122","author":"Homburger","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"R48-24-20241201","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/0016-5085(92)91518-9","article-title":"Frequency and significance of antibodies to liverkidney microsome type 1 in adults with chronic active hepatitis.","volume":"103","author":"Czaja","year":"1992","journal-title":"Gastroenterology"},{"key":"R49-24-20241201","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","article-title":"Chronic hepatitis. An update on terminology and reporting.","volume":"19","author":"Batts","year":"1995","journal-title":"Am J Surg Path"},{"key":"R50-24-20241201","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/0016-5085(93)91081-R","article-title":"Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis.","volume":"105","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R51-24-20241201","first-page":"1087","article-title":"Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.","volume":"20","author":"Soloway","year":"1975","journal-title":"Am J Dig Dis"},{"key":"R52-24-20241201","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.1840040409","article-title":"Complete resolution of inflammatory activity following corticosteroid treatment of HBsAgnegative chronic active hepatitis.","volume":"4","author":"Czaja","year":"1984","journal-title":"HEPATOLOGY"},{"key":"R53-24-20241201","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","article-title":"Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.","volume":"39","author":"Czaja","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R54-24-20241201","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1478-3231.2006.01387.x","article-title":"Clinical significance of HLA DRB103DRB104 in type 1 autoimmune hepatitis.","volume":"26","author":"MontanoLoza","year":"2006","journal-title":"Liver Int"},{"key":"R55-24-20241201","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve.","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"R56-24-20241201","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/BF01076196","article-title":"Severe chronic active liver disease. Prognostic significance of initial morphologic patterns.","volume":"22","author":"Schalm","year":"1977","journal-title":"Am J Dig Dis"},{"key":"R57-24-20241201","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0016-5085(88)90503-3","article-title":"Features reflective of early prognosis in corticosteroidtreated severe autoimmune chronic active hepatitis.","volume":"95","author":"Czaja","year":"1988","journal-title":"Gastroenterology"},{"key":"R58-24-20241201","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.20539","article-title":"Treatment challenges and investigational opportunities in autoimmune hepatitis.","volume":"41","author":"Czaja","year":"2005","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200710000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:06:21Z","timestamp":1733058381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200710000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21787","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}